NEWS

Correction

An April 3 News story ("Upstaging Tamoxifen? New Classes of Drugs Emerging for Breast Cancer", p. 474) incorrectly summarized the results of the Arimidex and Tamoxifen Alone or in Combination (ATAC) clinical trial. The trial found that, compared with tamoxifen alone, the aromatase inhibitor anastrozole statistically significantly reduced the relative risk of disease recurrence in postmenopausal women with early-stage breast cancer. The combination of anastrozole and tamoxifen was not statistically significantly different from tamoxifen alone. The Journal regrets the error.



             
Copyright © 2002 Oxford University Press (unless otherwise stated)
Oxford University Press Privacy Policy and Legal Statement